Research and development of 39 kinds of children's drugs will benefit from favorable policies

Source: Health Report 2017-06-01 our news (reporter Liu Zhiyong) on May 31, the website of the national health and Family Planning Commission issued a notice, printing and distributing the list of the second batch of drugs for children to encourage research and development and application jointly formulated by the national health and Family Planning Commission, the Ministry of industry and information technology and the State Food and drug administration The list includes 39 kinds of children's drugs that have not been registered and listed in the mainland and are urgently needed in clinic, in order to solve the current situation of the shortage of drug varieties, applicable dosage forms and specifications for children in China According to the several opinions on safeguarding children's drug use jointly issued by the national health and Family Planning Commission, the State Food and Drug Administration and other six departments, China will gradually establish a list of children's drugs to encourage research and development based on the needs of children's disease prevention and control, drawing on international experience, and incorporate it into the major science and technology special project of "major new drug creation" and major innovation and development of protein biological drugs and vaccines The project integrates the collaborative innovation and R & D of superior units, improves the independent innovation ability of the industry, guides and encourages enterprises to give priority to R & D and production; gives priority to supporting children's drug manufacturers to carry out product upgrading and production line technology transformation, promotes enterprises to improve the quality management system, improves product quality level, and ensures drug safety In June 2016, China released the list of the first batch of drugs for children to encourage R & D application Up to now, 71 kinds of children's drugs have been included in the list of drugs for children to encourage R & D application.